Maimonides Biomedical Research Institute of Cordoba
|Address||Edificio IMIBIC, Hospital Universitario Reina Sofía,
Av. Menéndez Pidal, s/n, 14004
|Platforms||ATMP & Biological, Biomarkers|
The Maimonides Biomedical Research Institute of Cordoba – IMIBIC, is a joint Institute of the University of Cordoba (UCO), the Reina Sofia University Hospital, and the Junta de Andalucía Regional government, created in 2008. It is structured in research groups commissioned by these institutions that cooperate in the implementation of the five scientific programmes, including Active aging and Fragility; Nutrition and endocrine and metabolic diseases; Infectious and immunological diseases and organ transplants; Cancer (Oncology and Oncohematology); and Chronic and Inflammatory Diseases.
IMIBIC brings together scientific research and medical practice to embrace integral projects with the ultimate aim to promote a much faster and efficient communication between clinical and preclinical research, and to generate knowledge of high impact with considerable potential of translation into practice, new therapies and innovative products.
One of the key activities at IMIBIC, and central for all its research programmes, is the identification, validation and development of biomarkers for the prevention, diagnosis and prognostic assessment of disease as well as for the prediction of therapy response. IMIBIC offers a wide range of biomarker technologies, namely state of the art Bioinformatics, Genomics, Proteomics, Lipidomics, and Flow cytometry and Imaging technologies. In addition, it offers services for the production of mesenchyme cells, and a series of pre-clinical, clinical development and target validation services. Clinical findings can be easily redirected into preclinical experimentation within the Animal Experimentation Unit.
IMIBIC is accredited within the framework of health research centres of excellence recognised by the National Institute of Health Carlos III.